They found that inhibition of FAS by using inhibitors (luteolin or C75) or the shRNA knockdown approach can down-regulate c-Met expression in human prostate cancer cells, and the production of the 16-carbon fatty acid palmitate by FAS is required for maintaining c-Met expression [31]. The gene discussed is MET; the disease is prostate carcinoma.